FeesSafety
Pluang+

Chegg reports Q3 2026 revenue drop but completes debt elimination and shifts focus to employability growth.

Company Fundamentals
03 Nov 2026, 15:05 WIB
GlobeNewsWire
View Source
Neutral
Chegg reports Q3 2026 revenue drop but completes debt elimination and shifts focus to employability growth.

Chegg reported Q3 2026 revenues of $46.5 million, down 40% year-over-year, with a net loss of $4.7 million. The company has eliminated its debt and holds $43.6 million in cash, marking a financial reset. Chegg is transforming from a homework help service to an employability platform, launching new features on Internships.com to help students find jobs and develop skills. The company expects continued investment in this area and projects Q4 revenues between $38 million and $40 million with adjusted EBITDA around $1 million, signaling a strategic shift towards growth in employability services.

Chegg's Q3 2026 revenues dropped 40% year-over-year to $46.5 million, with a net loss of $4.7 million as it shifts focus to employability services. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Nov 03, 2026 19:51 WIB: out of 134 priced US stocks, 40 rose and 85 fell. Notable movers include XPEV at USD 9.79 (+2.35%, 69% Sell / 31% Buy), BBWI at USD 22.68 (-2.20%, 100% Sell), and SFIX at USD 2.73 (-2.15%).

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
1 hour ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
1 hour ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
1 hour ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
2 hours ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App